canertinib has been researched along with hesperadin in 1 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (hesperadin) | Trials (hesperadin) | Recent Studies (post-2010) (hesperadin) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 58 | 0 | 33 |
| Protein | Taxonomy | canertinib (IC50) | hesperadin (IC50) |
|---|---|---|---|
| Aurora kinase A | Homo sapiens (human) | 0.011 | |
| Glucose transporter | Leishmania mexicana | 1.114 | |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | 0.78 | |
| Hexose transporter 1 | Plasmodium falciparum (malaria parasite P. falciparum) | 1.344 | |
| Solute carrier family 2, facilitated glucose transporter member 1 | Homo sapiens (human) | 1.434 | |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | 0.225 | |
| Aurora kinase B-A | Xenopus laevis (African clawed frog) | 0.003 | |
| Aurora kinase B | Homo sapiens (human) | 0.2006 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bharate, SB; Raghuvanshi, R | 1 |
1 other study(ies) available for canertinib and hesperadin
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases | 2022 |